HC Wainwright Analysts Increase Earnings Estimates for OBIO

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Stock analysts at HC Wainwright lifted their Q2 2026 earnings estimates for Orchestra BioMed in a research report issued on Thursday, May 14th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.38) per share for the quarter, up from their prior estimate of ($0.40). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.50) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.38) EPS and FY2027 earnings at ($1.57) EPS.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%.

Several other research firms also recently issued reports on OBIO. Weiss Ratings downgraded shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, March 12th. Barclays upped their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen cut shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.50.

Orchestra BioMed Price Performance

NASDAQ OBIO opened at $3.98 on Tuesday. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The company has a fifty day simple moving average of $4.28 and a 200 day simple moving average of $4.27. The company has a market cap of $238.32 million, a P/E ratio of -4.10 and a beta of 0.52. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $5.42.

Insider Transactions at Orchestra BioMed

In other Orchestra BioMed news, Director Eric S. Fain bought 20,000 shares of Orchestra BioMed stock in a transaction dated Thursday, May 14th. The shares were bought at an average price of $4.13 per share, with a total value of $82,600.00. Following the purchase, the director owned 91,709 shares of the company’s stock, valued at $378,758.17. This trade represents a 27.89% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider David P. Hochman purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the transaction, the insider directly owned 1,086,467 shares in the company, valued at $4,660,943.43. This trade represents a 0.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 7.50% of the company’s stock.

Institutional Trading of Orchestra BioMed

Several hedge funds have recently bought and sold shares of OBIO. NewEdge Advisors LLC acquired a new stake in shares of Orchestra BioMed in the second quarter valued at approximately $118,000. Balyasny Asset Management L.P. bought a new position in shares of Orchestra BioMed in the fourth quarter valued at $76,000. Qube Research & Technologies Ltd bought a new position in shares of Orchestra BioMed in the third quarter valued at $64,000. Virtu Financial LLC bought a new position in shares of Orchestra BioMed in the fourth quarter valued at $57,000. Finally, Jane Street Group LLC bought a new position in shares of Orchestra BioMed in the second quarter valued at $50,000. 53.20% of the stock is currently owned by institutional investors and hedge funds.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.